Olatec is a leading, clinical-stage biopharmaceutical company developing a platform of oral NLRP3 inhibitors to treat and prevent a broad spectrum of acute and chronic inflammatory diseases. The lead drug candidate, dapansutrile (lab code: OLT1177®) is a small molecule, specific NLRP3 inhibitor, currently in Phase 2/3 clinical development has demonstrated to date that it is well tolerated and shown to improve clinical outcomes in patients with acute gout flare (see The Lancet Rheumatology) and heart failure (see Journal of Cardiovascular Pharmacology). In the heart failure trial, treatment with dapansutrile in subset of subjects with diabetes led to clinically meaningful reductions in fasting glucose levels relative to placebo. Ongoing clinical trials are evaluating dapansutrile in Gout, Parkinson’s and Melanoma. For a complete list of Olatec’s original publications on dapansutrile in various preclinical and clinical disease areas, please refer to Olatec’s publications page, here. For more information, please visit http://www.olatec.com